Synucleinopathies are a group of brain diseases. They happen when a protein called alpha-synuclein builds up abnormally in nerve cells in the brain. This buildup causes problems in areas like the brain's control center for movement and thinking. It can lead to symptoms like Parkinson's disease or dementia.
Every report comes from a Lived member, sent anonymously.
Have you tried Levodopa for Synucleinopathies?
Synucleinopathies are a family of brain diseases in which a protein called alpha-synuclein folds abnormally and builds up in clumps, gradually damaging nerve cells. The term is an umbrella, not a single diagnosis. Its three main members are Parkinson's disease, Lewy body dementia (which includes dementia with Lewy bodies and Parkinson's disease dementia) and multiple system atrophy (MSA). These diseases share a protein problem and some symptoms, but they look different in daily life. Parkinson's disease mainly begins with slowness, stiffness, tremor and balance problems. Lewy body dementia affects thinking and alertness, often with vivid visual hallucinations and movement problems. MSA is rarer and progresses faster, combining movement or coordination problems with failure of the body's automatic controls, such as blood pressure and bladder function. Many people with a synucleinopathy also have symptoms outside movement and memory: acting out dreams during sleep, loss of smell, constipation, and dizziness on standing. Some of these can begin years before the condition is recognized. Knowing which disease is present matters, because outlook and treatment response differ.
Researchers do not yet know why alpha-synuclein begins to clump. In most people, the condition seems to arise from a mix of aging, genetic tendencies and environmental exposures rather than one cause. Age is the strongest risk factor: Parkinson's disease typically starts in the early to mid-60s, Lewy body dementia usually after 50, and MSA most often in a person's 50s. Men are affected somewhat more often than women. Genes play a larger role in Parkinson's disease than in the others. Changes in certain genes raise the risk, and a small number of families carry inherited forms. Most people with a synucleinopathy, however, have no clear family pattern, and no genetic test can predict whether someone will develop Lewy body dementia or MSA. Exposure to some pesticides and other pollutants is associated with a higher risk of Parkinson's disease, though an association does not mean that exposure caused an individual's illness. REM sleep behavior disorder, in which a person physically acts out dreams during REM (rapid eye movement) sleep, the stage when most vivid dreaming happens, is not a cause but an important early warning. In a large international study of people with this sleep disorder alone, about three in four had developed Parkinson's disease, Lewy body dementia or MSA within 12 years.
There is no single test for a synucleinopathy, and the diagnosis is usually of a specific disease rather than the umbrella term. A neurologist, ideally one experienced with movement disorders or dementia, builds the diagnosis from the pattern of symptoms, how they began and changed, and a detailed examination. Input from family members is useful, especially about sleep behavior, day-to-day swings in alertness and hallucinations. Tests support the clinical picture and rule out look-alikes. Brain MRI can exclude strokes or other structural causes and sometimes shows changes suggestive of MSA. A dopamine transporter (DaT) scan shows how the brain's dopamine-producing system is working, and this kind of imaging can help tell dementia with Lewy bodies apart from Alzheimer's disease. Blood pressure readings lying and standing, bladder testing and an overnight sleep study can reveal autonomic problems or REM sleep behavior disorder. How someone responds to levodopa is itself informative: a strong, lasting benefit points toward Parkinson's disease. Newer tests can detect abnormal alpha-synuclein directly, either in a small skin biopsy or in spinal fluid collected by lumbar puncture. Research shows they are among the most accurate markers available, but methods still vary between laboratories, and they add to rather than replace a full clinical assessment. Because early symptoms overlap, the diagnosis can change as the illness unfolds.
There is currently no cure for any synucleinopathy, and no treatment has been shown to slow the underlying protein buildup. Treatment can still ease many symptoms, keep people active longer and reduce complications such as falls. The plan depends on which disease is present and which symptoms matter most. For movement problems, levodopa (a medicine the brain converts into dopamine) is the mainstay. It usually works well in Parkinson's disease, helps some people with Lewy body dementia, and tends to help in MSA only partly or for a limited time. In Lewy body dementia it can worsen hallucinations, so it is started at a low dose and raised gradually. For thinking and attention, cholinesterase inhibitors, medicines that boost a memory-related brain chemical, can help; rivastigmine is FDA-approved for Parkinson's disease dementia. Side effects such as nausea, diarrhea and dizziness are common. Hallucinations and agitation need particular care in Lewy body dementia. People with this condition can react dangerously to antipsychotic medicines, with severe stiffness or, rarely, a life-threatening reaction. Older antipsychotics such as haloperidol generally should not be used, and if an antipsychotic is needed, specialists choose carefully among newer ones at the lowest dose for the shortest time. Hospital or emergency staff should always be told about the diagnosis. Much of the work is managing the body's automatic functions. Dizziness on standing can improve with compression stockings, more fluid and salt when a doctor advises it, smaller meals and sometimes blood-pressure-raising medicine. Constipation, bladder problems, sleep problems including dream enactment, and mood symptoms are treated individually; some bladder medicines can worsen confusion, so they are chosen cautiously. Physical, occupational and speech therapy help with mobility, home safety, voice and swallowing, and regular exercise is encouraged.
These are progressive conditions, but the pace varies widely between diseases and between people. Parkinson's disease often unfolds over many years, and many people keep working and living independently for a long time with treatment. Lewy body dementia lasts on average five to seven years from diagnosis, with a range of about two to 20 years. MSA advances faster: most people need a cane or walker within a few years of symptoms starting, and the illness typically progresses over five to ten years. As time goes on, help is usually needed with movement, daily tasks and decision-making. Falls, swallowing difficulty and confusion become more important, and swallowing problems can lead to pneumonia in later stages. In Lewy body dementia, alertness and thinking can swing from one day, or hour, to the next, which can be confusing for families. Fainting or lightheadedness on standing can shape routines, such as rising slowly and planning meals. Care works best as a team effort that may include a neurologist, primary care clinician, therapists, a sleep specialist and, over time, palliative care, which focuses on comfort and quality of life at any stage. Planning early for finances, driving, living arrangements and future medical wishes lets the person take part in those decisions. Caregivers carry a heavy load, and education, respite care and support groups help.
Arrange a medical evaluation for repeatedly acting out dreams (shouting, punching or falling out of bed during sleep), a new tremor or slowness of movement, changes in thinking or seeing things that are not there, or dizziness or fainting when standing. Mention loss of smell and longstanding constipation too, since together they help a neurologist interpret the picture. For someone already diagnosed, contact the care team promptly about any sudden or major change in abilities, alertness or behavior, since infection or a medicine may be responsible. Call the care team right away for a high fever with new muscle stiffness after starting an antipsychotic. Report coughing or choking during meals, or repeated falls, so swallowing and safety can be assessed before a serious injury or pneumonia occurs.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Synucleinopathies is like, what's helped you, or ask the community a question.